BriaCell Forms Medical Advisory Board Of Distinguished Breast Cancer Specialists To Advance Its Lead Oncology Candidate
Portfolio Pulse from Benzinga Newsdesk
BriaCell Therapeutics Corp. (NASDAQ:BCTX) has formed a medical advisory board and appointed three distinguished breast cancer specialists to advance its lead oncology candidate. The board includes Massimo Cristofanilli, MD, FACP, Sara A. Hurvitz, MD, FACP, and Adam M. Brufsky, MD, PhD. Charles Sidman, PhD, MBA, has also been added to its scientific advisory board. The company believes that these appointments will provide invaluable insights for their pivotal Phase 3 registration study.
October 25, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BriaCell Therapeutics Corp. has formed a medical advisory board with distinguished breast cancer specialists. This could potentially advance its lead oncology candidate and positively impact the company's stock.
The formation of a medical advisory board with distinguished specialists in the field of breast cancer could potentially advance BriaCell's lead oncology candidate. This could lead to positive clinical outcomes and increased investor confidence, potentially driving the company's stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100